Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Theravance Biopharma Inc | 170 |
| 2 | AstraZeneca PLC | 111 |
| 3 | Innoviva Inc | 104 |
| 4 | GSK PLC | 63 |
| 5 | Ligand Pharmaceuticals Inc | 44 |
| 6 | Pfizer Inc | 43 |
| 7 | Merck and Co Inc | 37 |
| 8 | Viatris Inc | 32 |
| 9 | AbbVie Inc | 31 |
| 10 | PTC Therapeutics Inc | 28 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 1,184 |
| 2 | A61K | Medicinal preparations | 1,017 |
| 3 | C07D | Heterocyclic compounds | 595 |
| 4 | C07K | Peptides | 212 |
| 5 | A61M | Devices for introducing media into the body | 110 |
| 6 | C12N | Microorganisms, enzymes | 105 |
| 7 | C07C | Acyclic and carbocyclic compounds | 80 |
| 8 | G01N | Investigating / analysing materials | 80 |
| 9 | Y02A | Climate change adaptation | 80 |
| 10 | C08L | Polymer compositions (blends) | 69 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee |
|---|---|---|
| Nejiyamas Ekomine Neji | 1983 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 2 |
| 2017 | 3 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Bo Åhrén | Lund University | 8 |
| 2 | Rubens Fazan | Universidade de São Paulo | 6 |
| 3 | Hugo Celso Dutra de Souza | Universidade de São Paulo | 5 |
| 4 | Nicholas Bodor | University of Florida | 4 |
| 5 | Paul S. Buckmaster | Stanford University | 4 |
| 6 | Cândido Celso Coimbra | Universidade Federal de Minas Gerais | 4 |
| 7 | Matthew D. Hall | National Institutes of Health | 4 |
| 8 | Umeko Marubayashi | Universidade Federal de Minas Gerais | 4 |
| 9 | Hélio César Salgado | Universidade de São Paulo | 4 |
| 10 | Thiago S. Moreira | Universidade de São Paulo | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Role of the Parasympathetic System in Airway Obstruction Due to Emphysema | 1984 | 262 | Asthma and respiratory diseases |
| Selective hepatic vagotomy blocks pancreatic glucagon's satiety effect | 1983 | 134 | Gastrointestinal motility and disorders |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of methylatropine nitrate?
Which companies hold the most patents for methylatropine nitrate?
What are the primary patent classification areas for methylatropine nitrate research?
How has patent activity for methylatropine nitrate trended in recent years?
What research topics are associated with methylatropine nitrate publications?